---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010960"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:27:45.704018+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Q2 net revenue $172.8M (+29% YoY); non-GAAP EPS $1.05 vs $0.76; FY guidance reaffirmed

## Summary
- Net product revenue $172.8M for Q2 2024, up 29% from $134.2M in Q2 2023.
- GAAP net income $11.6M ($0.20 diluted EPS) vs $34.3M ($0.56) prior year; non-GAAP adjusted net income $60.6M ($1.05 diluted EPS) vs $45.9M ($0.76).
- Average patients on WAKIX increased sequentially by ~250 to approximately 6,550 for the quarter.
- FY 2024 net product revenue guidance reiterated at $700-$720 million.
- FDA approved WAKIX for pediatric narcolepsy (EDS) on June 21, 2024; commercial launch began July 1.

## SEC filing metadata
- accession: 0001558370-24-010960
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837024010960/0001558370-24-010960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837024010960/hrmy-20240806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010960
- JSON: https://secwatch.observer/filing/0001558370-24-010960.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.